Retatrutide may prove to be a significant advance in obesity medicine once full Phase 3 trial data are available and regulatory review is complete, but until that point, decisions about weight management should be guided by your healthcare team using currently licensed, evidence-based options
As of September 2025, the FDA has reported more than 1,400 adverse events linked to compounded GLP-1s, including over 300 hospitalizations and at least 23 deaths
Sagging and loose skin A second priority for patients with GLP-1 facial changes would be skin tightening for skin laxity, particularly in the cheeks, jawline and neck
This depends on how long it has been since your scheduled dose
"And if we target this mechanism, this preliminary evidence suggests that it may be helpful for migraine." The success of this pilot study paves the way for larger trials